Rycarfa vet.

1 x 20 ml

Liquid for injection, solution

Active substance

Carprofen : 50 mg/ml

ATC code

QM01AE91 Carprofen

QM01AE Propionic acid derivatives

QM01A Antiinflammatory and antirheumatic products, non-steroids (NSAIDs)

QM01 Antiinflammatory and antirheumatic products

QM Musculo-skeletal system

Species

Dogs and cats.

Indications

Dogs: For the control of post-operative pain and inflammation following orthopaedic and soft tissue (including intraocular) surgery.

Cats: For the control of post-operative pain following surgery.

Dose to be administered and administration route

Intravenous and subcutaneous use.

Dogs: The recommended dosage is 4.0 mg carprofen/kg bodyweight (1 ml/12.5 kg bodyweight). The veterinary medicinal product is best given pre-operatively, either at the time of premedication or induction of anaesthesia.

Cats: The recommended dosage is 4.0 mg/kg (0.24 ml/3.0 kg bodyweight), best given pre-operatively at the time of induction of anaesthesia. The use of a 1 ml graduated syringe is recommended to measure the dose accurately.

Clinical trial evidence in dogs and cats suggests only a single dose of carprofen is required in the first 24 hours perioperatively; if further analgesia is required in this period a half dose (2 mg/kg) of carprofen may be given to dogs (but not to cats) as necessary.

To ensure a correct dosage, body weight should be determined as accurately as possible.

In dogs, to extend analgesic and anti-inflammatory cover post-operatively, parenteral therapy may be followed with carprofen tablets at 4 mg/kg/day for up to 5 days.

For administration of the veterinary medicinal product a 21-gauge needle should be used.

The cap can be punctured up to 20 times. When puncturing more than 20 times, use a draw-off needle.

Adverse reactions

Dogs and cats:

Rare

(1 to 10 animals / 10,000 animals treated):

Renal disorder

Hepatic disorder¹

Undetermined frequency (cannot be estimated from the available data):

Vomiting ², loose stool ², diarrhoea ², blood in faeces ^2,3, appetite loss ²

Lethargy ²

Injection site reaction ⁴

¹ Idiosyncratic reaction.

² Generally occur within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

³ Occult

⁴ Following subcutaneous injection.

If adverse reactions occur, use of the veterinary medicinal product should be stopped and the advice of a veterinarian should be sought.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.